Q-omics provides the consensus-scored FAM153A profile across patient tissues and cancer cell-line models. FAM153A expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FAM153A is differentially expressed in 8, with the highest sampling consensus in KIRC. Additionally, FAM153A RNA expression shows 13,254 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, KIRC, and THYM as cancer lineages where FAM153A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM153A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM153A survival associations across molecular data types. FAM153A RNA expression shows survival associations in the most cancer types (19), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM153A RNA expression–survival associations across cancer types. High FAM153A expression shows unfavorable associations in KIRP, UCEC and STAD, but favorable associations in ACC, HNSC and MESO. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify ACC as the clearest survival context for FAM153A RNA expression.
This table summarizes FAM153A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for FAM153A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM153A shows lower tumor expression in STAD, UCEC, BRCA, COAD and LUSC and higher tumor expression in KIRC. The KIRC box plot shows higher FAM153A RNA expression in tumor versus normal tissue (log2 FC = +0.398, t-test p < 0.001).
This table shows molecular features associated with FAM153A in patient tissues and cancer cell lines. In patient samples, FAM153A shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM153A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
